ACEA Biosciences, Inc Sustainability Profile
ACEA Biosciences, Inc., a leading innovator in the life sciences industry, is headquartered in the United States, with significant operational presence across various global markets. Founded in 2002, the company has established itself as a pioneer in cell analysis and assay technologies, focusing on advancing research in drug discovery and development. ACEA Biosciences is renowned for its cutting-edge products, including the xCELLigence® Real-Time Cell Analysis (RTCA) system, which offers unique capabilities for monitoring cellular behaviour in real-time. This technology sets ACEA apart, enabling researchers to gain deeper insights into cellular responses and interactions. With a strong market position, ACEA Biosciences has achieved notable milestones, including collaborations with leading pharmaceutical companies and academic institutions, solidifying its reputation as a trusted partner in the life sciences sector.
DitchCarbon Score
How does ACEA Biosciences, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ACEA Biosciences, Inc's score of 64 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ACEA Biosciences, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Agilent Technologies, Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Agilent Technologies, Inc. has established various climate initiatives, including Science Based Targets Initiative (SBTi) commitments and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for ACEA Biosciences, Inc. have not been detailed in the available information. As a subsidiary, ACEA Biosciences may align its climate strategies with those of Agilent Technologies, which is actively working towards reducing its carbon footprint and enhancing sustainability practices. The lack of direct emissions data suggests that ACEA Biosciences is in the process of developing its own climate commitments or may rely on the overarching strategies set by Agilent Technologies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 14,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 108,100,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is ACEA Biosciences, Inc's Industry?
How Carbon Intensive is ACEA Biosciences, Inc's Location?
ACEA Biosciences, Inc's Scope 3 Categories Breakdown
ACEA Biosciences, Inc's Scope 3 emissions, which decreased by 18% last year and decreased by approximately 41% since 2016, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 56% of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" being the largest emissions source at 88% of Scope 3 emissions.
Top Scope 3 Categories
ACEA Biosciences, Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ACEA Biosciences, Inc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
